[{"address1": "Azrieli Center", "address2": "Building D 26 Harokmim Street", "city": "Holon", "zip": "5885849", "country": "Israel", "phone": "972 3 765 8585", "fax": "972 3 765 8555", "website": "https://cgen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with na\u00efve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Dr. Anat  Cohen-Dayag Ph.D.", "age": 56, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 796519, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zurit  Levine Ph.D.", "age": 55, "title": "Senior Vice President of Technology Innovation", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 345697, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.65, "open": 2.72, "dayLow": 2.72, "dayHigh": 3.03, "regularMarketPreviousClose": 2.65, "regularMarketOpen": 2.72, "regularMarketDayLow": 2.72, "regularMarketDayHigh": 3.03, "beta": 2.65, "forwardPE": -8.909091, "volume": 1717133, "regularMarketVolume": 1717133, "averageVolume": 2975575, "averageVolume10days": 1121630, "averageDailyVolume10Day": 1121630, "bid": 2.9, "ask": 3.0, "bidSize": 1300, "askSize": 800, "marketCap": 263218800, "fiftyTwoWeekLow": 0.53, "fiftyTwoWeekHigh": 3.03, "priceToSalesTrailing12Months": 35.09584, "fiftyDayAverage": 2.1834, "twoHundredDayAverage": 1.2897, "currency": "USD", "enterpriseValue": 204418464, "floatShares": 83449728, "sharesOutstanding": 89530200, "sharesShort": 2018793, "sharesShortPriorMonth": 1595776, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0229, "heldPercentInsiders": 0.00064000004, "heldPercentInstitutions": 0.13937001, "shortRatio": 2.83, "shortPercentOfFloat": 0.0229, "impliedSharesOutstanding": 88442704, "bookValue": 0.603, "priceToBook": 4.8756223, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -31559000, "trailingEps": -0.41, "forwardEps": -0.33, "enterpriseToRevenue": 27.256, "enterpriseToEbitda": -6.011, "52WeekChange": 2.630137, "SandP52WeekChange": 0.33757293, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CGEN", "underlyingSymbol": "CGEN", "shortName": "Compugen Ltd.", "longName": "Compugen Ltd.", "firstTradeDateEpochUtc": 966000600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "1985262d-ab80-3c43-a2e1-6782924ab738", "messageBoardId": "finmb_166115", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.94, "targetHighPrice": 7.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.33, "targetMedianPrice": 5.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 57507000, "totalCashPerShare": 0.651, "ebitda": -34007248, "totalDebt": 1410000, "quickRatio": 5.809, "currentRatio": 5.809, "totalRevenue": 7500000, "debtToEquity": 2.649, "revenuePerShare": 0.086, "returnOnAssets": -0.2583, "returnOnEquity": -0.47441003, "grossMargins": 0.87, "operatingMargins": -4.60067, "financialCurrency": "USD", "trailingPegRatio": null}]